118 related articles for article (PubMed ID: 9252661)
1. A streptococcal preparation (OK-432) enhances monoclonal antibody NCC-ST-421 cytotoxicity against human colon cancer.
Kawano Y; Watanabe M; Kubota T; Nishibori H; Kurihara N; Teramoto T; Kitajima M
Anticancer Res; 1997; 17(4A):2449-53. PubMed ID: 9252661
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody to a human salivary gland adenocarcinoma cell line: augmentation of antibody-dependent cell-mediated cytotoxicity activity by streptococcal preparation OK-432 in human salivary gland adenocarcinoma-bearing nude mice given the antibody.
Kaji R; Yoshida H; Yanagawa T; Sato M
J Biol Response Mod; 1989 Oct; 8(5):488-500. PubMed ID: 2552025
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
6. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of murine monoclonal antibody NCC-ST-421 on human cancer cells by inducing apoptosis.
Ishizuka H; Watanabe M; Kubota T; Matsuzaki SW; Otani Y; Kitajima M
Anticancer Res; 1998; 18(4A):2513-8. PubMed ID: 9703902
[TBL] [Abstract][Full Text] [Related]
8. Synergetic effect of interleukin-2 and cellular cytotoxicity against a novel tumor-associated carbohydrate antigen Le(a)/Le(a) (dimeric Le(a)) mediated by monoclonal antibody NCC-ST-421 in adoptive immunization using SCID mice.
Watanabe M; Kubota T; Kitajima M; Hakomori S
Cancer Immunol Immunother; 1993 Sep; 37(4):245-50. PubMed ID: 8348564
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody to the streptococcal preparation OK-432: tissue OK-432 localization and analysis of interaction between OK-432 and macrophages or NK cells in human salivary adenocarcinoma-bearing nude mice given OK-432.
Sato M; Kaji R; Urata M; Yoshida H; Yanagawa T; Miyamoto K; Azuma M; Furumoto N; Saito M
J Biol Response Mod; 1988 Apr; 7(2):212-28. PubMed ID: 3361352
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
11. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion.
Hihara J; Yamaguchi Y; Minami K; Noma K; Toge T
Anticancer Res; 1999; 19(2A):1077-84. PubMed ID: 10368657
[TBL] [Abstract][Full Text] [Related]
13. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effect of antibody against a SEREX-defined antigen (UOEH-LC-1) on lung cancer xenotransplanted into severe combined immunodeficiency mice.
Mizukami M; Hanagiri T; Yasuda M; Kuroda K; Shigematsu Y; Baba T; Fukuyama T; Nagata Y; So T; Ichiki Y; Sugaya M; So T; Takenoyama M; Sugio K; Yasumoto K
Cancer Res; 2007 Sep; 67(17):8351-7. PubMed ID: 17804751
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
Oshikawa T; Okamoto M; Ohe G; Furuichi S; Nishikawa H; Uddin Ahmed S; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
[TBL] [Abstract][Full Text] [Related]
16. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
17. [Local immunotherapy for cancer].
Hattori T; Niimoto M; Toge T; Hamamoto S; Seto Y; Kameda A; Tomoda S
Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1157-61. PubMed ID: 6503978
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
Ono T; Harada M; Yamada A; Tanaka M; Takao Y; Tanaka Y; Mine T; Sakamoto K; Nakashima T; Itoh K
Clin Cancer Res; 2006 Feb; 12(4):1325-32. PubMed ID: 16489090
[TBL] [Abstract][Full Text] [Related]
19. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
20. Studies of methotrexate-monoclonal antibody conjugates for immunotherapy.
Kanellos J; Pietersz GA; McKenzie IF
J Natl Cancer Inst; 1985 Aug; 75(2):319-32. PubMed ID: 2991647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
